Main menu


Production and transfer of intellectual property, technology and know-how

featured image

At the second meeting Intergovernmental negotiating body for drafting and negotiating WHO conventions, agreements or other international instruments on pandemic prevention, preparedness and response (INB) for the INB Bureau to conduct informal and focused consultations (IFC) with experts, open to all WHO Member States and relevant stakeholders, on selected issues of importance. decided to

All IFCs are fully virtual and interpreted in all WHO official languages. Each Chair is co-chaired by his INB Bureau and consists of his two parts:

  1. Interactive moderated roundtables between independent experts, where moderators ask questions and stimulate input from experts and inter-expert dialogue.When
  2. Discussion and reflection sessions for Member States and relevant stakeholders. Questions and considerations can be sent via email or the meeting’s “chat” feature.

Four IFCs are scheduled. The third focuses on the production and transfer of intellectual property, technology and know-how.

Date and time: October 7, 2022 14:00-17:00

topics to cover

  • Research and Development
  • Access to patents and technology, including related know-how
  • Role of TRIPS, Compulsory Licenses and Intellectual Property Waivers
  • Capacity and supply chain considerations
  • Emergency regulatory approval

Chair: Precious Matsoso, INB Bureau Co-Chair and Roland Driece, INB Bureau Co-Chair

Moderator: Emma Ross, Senior Fellow, Chatham House, Royal Institute of International Affairs, London, United Kingdom of Great Britain and Northern Ireland

Participating experts


  • Richard HatchettCEO, Coalition for Epidemic Preparedness Innovations (CEPI)
  • Carlos CorreaSouth Center Managing Director
  • Padmashree Gael SampathHarvard Berkman Klein Center Global Access in Action Program Fellow and Senior Advisor, COVID-19 Technology Access Pool (CTAP) Technical Advisory Group Chairperson
  • Ellen To HoenDirector, Medicines Law & Policy / Global Health Law Fellow Fatal, University of Groningen, Netherlands
  • Mozycera adiaiNigerian Food and Drug Administration (NAFDAC) Commissioner, Nigeria
  • Martin Harvey AllchurchEuropean Medicines Agency, Head of International Relations

WHO Secretariat

  • Sumia SwaminathanChief Scientist
  • Mariangela SimoneAssistant Director-General of WHO, Access to Medicines and Health Products

Additional Information

Bearing in mind the informal nature of IFC and the goal of promoting full and candid discussion, the following applies to all IFC sessions:

  • Discussions at IFC sessions involving participating experts are in no way prejudicial to Member States or other session participants.
  • Comments or questions posed by session participants, including member countries, during IFC do not imply the views or positions of member countries or other session participants.When
  • Expert presentations are provided for Member State consideration only, and do not themselves serve as a source of input to the Concept Zero Draft.